Trevi Therapeutics (TRVI) Soars as Haduvio Taps Into $15B Addressable Market
Trevi Therapeutics (NASDAQ:TRVI) shares rose 9.85% to $19.07 after management highlighted clinical results for Haduvio, an extended-release nalbuphine oral treatment for refractory chronic cough (RCC) and idiopathic pulmonary fibrosis (IPF). The company cited a $14B to $15B chronic cough market by 2035. It plans a Phase 2b trial in 2H 2026.
How this was made
The 30-second read
Why it matters
Management’s conference remarks and the stated plan for a Phase 2b adaptive design trial in 2H26 provide a clearer catalyst calendar, supporting a higher probability-weighting for future clinical readouts.
Market read
For TRVI traders, the actionable items are the implied strengthening of the clinical narrative plus the explicit 2H26 initiation and 2H27 topline timing for a follow-on Phase 2b study.
What to watch
Key risk is translational and regulatory uncertainty: Phase 2b adaptive design for non-IPF ILD-related chronic cough is planned for 2H26, leaving a long gap where efficacy, safety, and trial design outcomes could disappoint.
Background
Trevi Therapeutics is developing Haduvio, an extended-release formulation of nalbuphine, for chronic cough indications including refractory chronic cough and IPF.
Ticker impact
Trevi’s CEO and CDO highlighted positive clinical trial results for Haduvio in refractory chronic cough and IPF, driving a 9.85% Friday rally.
Bullish bias near-term, with upside skew if investors treat the conference data as strengthening the probability of later trial success; volatility likely into 2H26/2H27 milestones.
A same-day price move is attributed to management’s clinical-trial highlights, and the text adds concrete future trial initiation and topline timing, but it does not provide new numeric efficacy endpoints or regulatory filings.
Market effects
Reinforces investor appetite for opioid-derived extended-release therapies in chronic cough and ILD-related cough, potentially lifting sentiment for similar respiratory pipeline names.
Limited direct regional read-through; conference commentary is Europe-based but the catalyst is company-specific.
Global addressable-market framing (US, UK, EU, Japan) may support broader chronic cough treatment theme interest, though it is not a cross-company datapoint.
Counterpoint
The article emphasizes market opportunity and qualitative trial success without disclosing new endpoint numbers or regulatory progress, so the rally may be sentiment-driven rather than fundamentally re-rated.
Key entities
- public_companyTrevi Therapeutics
NASDAQ-listed developer of Haduvio; shares rose 9.85% on Friday after management highlighted clinical trial results and next trial plans.
- product_candidateHaduvio
Extended-release nalbuphine oral treatment candidate for refractory chronic cough and IPF; positioned as potentially company-defining if approved.
